PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity

Yan Sun, Jufeng Guo, Lei Yu, Tianxin Guo, Jiaoli Wang, Xian Wang, Yinghu Chen

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Tumors escape immune attack by upregulating the surface expression of PD-L1, which interacts with PD-1 on T cells to activate immune inhibitory signaling. Anti-PD-1 treatments can effectively block this inhibitory signaling and activate antitumor immune responses. However, anti-PD-1 treatment also has a tumor suppressive effect in patients whose tumor cells do not express PD-L1. The underlying mechanisms are poorly defined. Here, we report that exosomes from bone marrow-derived cells (BMDCs) in tumor-bearing mice, but not in healthy mice, carry PD-L1. PD-L1 on these exosomes is biofunctional and can inhibit CD8+ T cell proliferation and activation in vitro and in vivo. The transfer of exogenous exosomes from BMDCs and the inhibition of the production of endogenous exosomes by BMDCs promote and suppress tumor growth, respectively. PD-L1+ exosomes from BMDCs can be found in tumor tissues. In addition, exosomes from BMDCs promote tumor metastasis in a PD-L1-dependent manner. Therefore, our results indicate that exosomes from BMDCs play important roles in tumor immunosuppression via PD-L1.

Original languageEnglish
Pages (from-to)2402-2409
Number of pages8
JournalCellular and Molecular Immunology
Issue number10
StatePublished - Oct 2021


  • Bone marrow-derived cells
  • Exosomes
  • PD-L1


Dive into the research topics of 'PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity'. Together they form a unique fingerprint.

Cite this